These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33645308)

  • 1. Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial.
    Cross AJ; Myles J; Greliak P; Hackshaw A; Halloran S; Benton SC; Addison C; Chapman C; Djedovic N; Smith S; Wagner CV; Duffy SW; Raine R
    J Med Screen; 2021 Dec; 28(4):419-425. PubMed ID: 33645308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial.
    Hewitson P; Ward AM; Heneghan C; Halloran SP; Mant D
    Br J Cancer; 2011 Aug; 105(4):475-80. PubMed ID: 21829202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the effectiveness of GP endorsement on increasing participation in the NHS Bowel Cancer Screening Programme in England: study protocol for a randomized controlled trial.
    Damery S; Smith S; Clements A; Holder R; Nichols L; Draper H; Clifford S; Parker L; Hobbs R; Wilson S
    Trials; 2012 Feb; 13():18. PubMed ID: 22348399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
    Raine R; Duffy SW; Wardle J; Solmi F; Morris S; Howe R; Kralj-Hans I; Snowball J; Counsell N; Moss S; Hackshaw A; von Wagner C; Vart G; McGregor LM; Smith SG; Halloran S; Handley G; Logan RF; Rainbow S; Smith S; Thomas MC; Atkin W
    Br J Cancer; 2016 Feb; 114(3):321-6. PubMed ID: 26742011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.
    Wardle J; von Wagner C; Kralj-Hans I; Halloran SP; Smith SG; McGregor LM; Vart G; Howe R; Snowball J; Handley G; Logan RF; Rainbow S; Smith S; Thomas MC; Counsell N; Morris S; Duffy SW; Hackshaw A; Moss S; Atkin W; Raine R
    Lancet; 2016 Feb; 387(10020):751-9. PubMed ID: 26680217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.
    Raine R; Moss SM; von Wagner C; Atkin W; Hans IK; Howe R; Solmi F; Morris S; Counsell N; Hackshaw A; Halloran S; Handley G; Logan RF; Rainbow S; Smith S; Snowball J; Seaman H; Thomas M; Smith SG; McGregor LM; Vart G; Wardle J; Duffy SW
    Br J Cancer; 2016 Dec; 115(12):1479-1486. PubMed ID: 27875518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.
    Smith SG; Wardle J; Atkin W; Raine R; McGregor LM; Vart G; Morris S; Duffy SW; Moss S; Hackshaw A; Halloran S; Kralj-Hans I; Howe R; Snowball J; Handley G; Logan RF; Rainbow S; Smith S; Thomas M; Counsell N; von Wagner C
    BMC Cancer; 2017 Aug; 17(1):543. PubMed ID: 28806955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
    Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
    Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing bowel cancer screening using SMS in general practice: the SMARTscreen cluster randomised trial.
    McIntosh JG; Jenkins M; Wood A; Chondros P; Campbell T; Wenkart E; O'Reilly C; Dixon I; Toner J; Martinez-Gutierrez J; Govan L; Emery JD
    Br J Gen Pract; 2024 Apr; 74(741):e275-e282. PubMed ID: 38164588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the effectiveness and cost-effectiveness of text-message reminders and telephone patient navigation to improve the uptake of faecal immunochemical test screening among non-responders in London: a randomised controlled trial protocol.
    Duffy T; Gil N; Siddique B; Duffy S; Prentice A; Marshall S; Djedovic NK; Lewis M; Ruwende J; von Wagner C; Kerrison R
    BMJ Open; 2024 Jun; 14(6):e079482. PubMed ID: 38909999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England.
    Benton SC; Piggott C; Blyuss O; Li SJ; Mathews C; Carroll M; Duffy S
    J Med Screen; 2021 Dec; 28(4):426-432. PubMed ID: 33983066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner.
    Cole SR; Young GP; Byrne D; Guy JR; Morcom J
    J Med Screen; 2002; 9(4):147-52. PubMed ID: 12518003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General practitioner endorsement of mail-out colorectal cancer screening: The perspective of nonparticipants.
    Goodwin BC; Crawford-Williams F; Ireland MJ; March S
    Transl Behav Med; 2020 May; 10(2):366-374. PubMed ID: 30855076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
    Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
    Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population.
    Kaushal A; Hirst Y; Tookey S; Kerrison RS; Marshall S; Prentice A; Vulkan D; Duffy S; von Wagner C
    Prev Med; 2020 Dec; 141():106268. PubMed ID: 33022321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a Doctor's Invitation on Participation in Colorectal Cancer Screening: A Cluster Randomized Trial.
    Barthe J; Perrodeau E; Gilberg S; Ravaud P; Ghasarossian C; Marchand-Buttin F; Deyra J; Falcoff H
    Am J Med; 2015 Sep; 128(9):1024.e1-7. PubMed ID: 25908395
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.